Dri Healthcare Trust T.DHT.UN

Alternate Symbol(s): DHTRF

Healthcare Biotechnology

DRI Healthcare Trust is a Canada-based company engaged in global pharmaceutical royalty monetization. The Company is involved in pharmaceutical royalty monetization and provides capital to inventors, academic institutions and biopharma companies. It acquires more than 25 royalties on 20-plus drugs, including Eylea, Orserdu, Omidria, Spinraza, Stelara, Vonjo, Zejula and Zytiga. Its portfolio includes Empaveli/Syfovre, Eylea I, Eylea II, Ilaris, Natpara, Omidria, Oracea, Orserdu I, Orserdu II, Rydapt, Simponi, Spinraza, Stelara, Vonjo I, Vonjo II, Xenpozyme, Xolair, Zejula, Zytiga, sebetralstat, and others. Its therapeutic areas include hematology, ophthalmology, influenza, endocrinology, dermatology, oncology, neurology, immunology, lysosomal storage disorder, hereditary angioedema, and others. The Company is managed by DRI Capital Inc. Its products are marketed by pharmaceutical companies, including Regeneron, Bayer, Santen; AstraZeneca; Takeda; Galderma Laboratories; and others.

TSX:DHT.UN - Post by User

Dri Healthcare Trust

<< Previous

Bullboard Posts

Next >>

(12)
•••

Comment by raybay_98on Apr 25, 2025 12:41pm

79 Views

Post# 36551225

RE:RE:RE:RE:RE:RE:T3 Error Update

As the old saying goes, " One Shoe Dropped, When Will The Second Shoe Drop?", and there-in lies the problem imo. It appears this carcas can only attract flies, not looking good or smelling good. JMHO

<< Previous

Bullboard Posts

Next >>

The 5-Minute Investor Podcast, Ep. 15: Ferroglobe and HPQ Silicon